N338 Medication List February 5, 2021 Med Class Route & Freq Dosage *Include the recommended dosage range for this age group Diluted Un-Diluted Diluted amt. Minutes for injection Why is this pt. taking? Side Effects Medical DX NSG DX Assessment Lab Before Giving *Hold if: After Giving Assess SE & Expected Outcomes (what should the med do) Insulin lispro, Humalog Insulin (rapid acting) SC 0.5-1.2 units/kg/day Onset: w/in 15min Peak:1-2hrs Duration:3-4hrs Type I/ II Diabetes Hypoglycemia Hypoglycemic, Hold if NPO and BGL <60mg/dl Insulin aspart, Novolog Insulin (rapid acting) SC 0.5-1 units/kg/day Onset: w/in 15min Peak: 1-2hr Duration: 3-4hr Type I/II Diabetes Hypoglycemia Hypoglycemic, Hold if NPO and BGL <60mg/dl S/S of hypoglycemia: (sweating, hunger, weakness, dizziness, anxiety) Expected: control of blood glucose levels S/S of hypoglycemia Expected: control of blood glucose levels NPH Insulin (intermediate) SC Type I/II Diabetes Hypoglycemia Hypoglycemic, Hold if NPO and BGL <60mg/dl S/S of hypoglycemia Expected: control of blood glucose levels Insulin glargine, Lantus Insulin (long acting) SC 0.5-1 unit/kg/day Onset: 2-4hr Peak:4-10hr Duration: 10-16hr Type I: 0.2-0.4 units/kg Type II: 0.2 units/kg or up 10 units/daily Onset: 3-4hr Peak: none Duration: 24hr Adults: 1.25-20mg/day Geriatric: 1.252.5mg/day Onset: 45-60min Peak: 1.5hr-3hr Duration: 24hr 500mg bid Onset: unknown Peak: unknown Duration: 12 hr. Type I/II Diabetes Hypoglycemia Hypoglycemic, Hold if NPO and BGL <60mg/dl S/S of hypoglycemia glyburide T: antidiabetics PO metformin T: antidiabetics PO ketorolac T: nonsteroidal antiinflammatory agents, nonopioid analgesics PO, IM, IV, Intran asal T: antipyretics nonopioid analgesics PO, IV, Rect acetaminophen, Tylenol PO (Adult<65yr): 20 mg, 40 mg/day MAX IM (Adult <65yr): 60mg, 120 mg/day MAX IV (Adults <65yr): 30mg, 120 mg/day MAX IV Push: Undiluted, 1530mg, over 15 sec Intranasal (Adults <65yr): 1 spray q 6-8h, 4 sprays/ day MAX PO (Adults/ Children >12yrs): 325-650mg q6h, 4g/day MAX for all routes, 2-3g/day MAX in hepatic/ renal impairment IV (Adults/ Children >13yr/ >50kg): 1000mg q6h Type II Diabetes Type II Diabetes Acute pain Acute pain, imbalanced body temperature Expected: control of blood glucose levels Erythema multiforme, photosensitivit y, hypoglycemia, aplastic anemia Lactic Acidosis, abdominal bloating, diarrhea, nausea, vomiting Hypoglycemic, Hold if NPO and BGL <60mg/dl S/S of hypoglycemia Hypoglycemic, Hold if NPO and BGL <60mg/dl S/S of hypoglycemia, ketoacidosis, lactic acidosis Expected: control of blood glucose levels w/o appearance of hypoglycemic or hyperglycemic episodes Drowsiness, Myocardial Infarction, Stroke, Exfoliative Dermatitis, GI Bleeding Pain assessment, BP, Hold if active or history of peptic ulcer diseases or GI bleeding and concurrent use of pentoxifylline or probenecid Assess for rash, pain level 1-2hr after administration, monitor BP Hepatotoxicity, Acute generalized exanthematous pustulosis, StevensJohnson Syndrome Pain and fever assessment, Hold if severe hepatic impairment/ active liver disease and rash occurs during therapy Assess for rash, and pain level 30-60 min after administration Expected: Relief to mild to moderate pain and reduction of fever Expected: lowering of blood sugar levels Expected: Decrease in severity of pain ibuprofen, Advil T: antipyretics, antirheumatics, nonopioid analgesics, NSAID PO, IV hydromorphone, Dilaudid T: opioid analgesics, antitussives PO, SC, IM, IV, Rect T: opioid analgesics PO, IM, SC, Rect, IV, Epi T: Antitussive, opioid analgesics PO oxycodone/ acetaminophen, Percocet Antidote: Naloxone (Narcan) T: Opioid analgesics PO lorazepam, Ativan T: antianxiety agents, sedative P: benzodiazepine s PO, IM, IV diazepam, Valium T: antianxiety agents, anticonvulsants P: benzodiazepine s PO, IM, IV Antidote: Naloxone (Narcan) morphine Antidote: Naloxone (Narcan) hydrocodone/ acetaminophen, Vicodin Rect (Adults/ Children >12yr): 325-650mg q46h PO (Adults): Antiinflammatory-400800mg 3-4 times/day, 3200mg MAX IV (Adults): Analgesic400-800mg q6h PRN Antipyretic- 400mg q46hr Dilute- 4mg/mL and a rate of 30 min PO (Adults >50kg): Immediate-release- 48mg q3-4h IV IM SC (Adults >50kg): 1.5 mg q3-4h PRN Rect (Adults): 3mg q68hr PRN IV Push: Undiluted, 23min rate PO RECT (Adult >50kg): Starting dose- 30mg q34hr IM IV SC (Adult >50kg): Starting dose- 0.05-0.2 mg/kg q3-4h; 15 mg/dose MAX Epi (Adults): 5mg/day, undiluted IV Push: Undiluted, 2.515 mg/ 5min rate Acute pain, impaired physical mobility, imbalanced body temperature Headache, Myocardial Infarction, Stroke, GI Bleeding, constipation, dyspepsia, nausea, vomiting Pain and fever assessment, Hold if active GI bleeding or ulcer disease, history of MI Assess for rash, pain level 1-2hr following administration Expected: Decrease in severity of pain, improved joint mobility, reduction of fever Acute pain, chronic pain Confusion, sedation, hypotension, constipation, resp. depression BP, pulse, resp. rate, pain assessment Hold if resp. rate <10/min, paralytic ileus Acute pain, chronic pain Confusion, sedation, hypotension, constipation, resp. depression BP, pulse, resp. rate, pain assessment Hold if resp. rate <10min, paralytic ileus PO (Adults): Analgesic2.5-10 mg q3-6h PRN Antitussive- 5mg q4-6hr PRN Acute pain, chronic pain Confusion, dizziness, sedation, hypotension, constipation , nausea, resp. depression, hepatotoxicity BP, pulse, resp. rate, pain assessment Hold if paralytic ileus, resp. rate <10 min Assess BP, pulse. Resp. rate, and pain level 1 hr. after administration IM/ PO and 5 min after IV admin, bowel function Expected: Decrease in severity of pain, suppression of cough Pain assessment 1 hr. after admin PO, SC, IM and 20 min after IV admin, assess level of consciousness, BP, pulse, resp. rate, bowel function Expected: Decrease in severity of pain, decrease in symptoms of pulmonary edema BP, pulse, resp. rate, bowel function, pain assessment 1hr after admin Expected: Decrease in severity of pain, suppression of nonproductive cough PO (Adults >50kg): Opioid-native pts-510mg q3-4h PRN, 4g/day MAX, 2-3g/day MAX in hepatic/renal impairment IV IM (Adults): Status Epilepticus-4mg PO (Adult): Anxiety-13mg, 2-3 times/day, 10mg/day MAX Insomnia- 2-4mg hs IV Push: Dilute w/ equal amount of sterile water, rate is 2mg/min PO (Adults): 2-10mg, 24 times/day IM IV (Adults): 2-10mg, may repeat 3-4hr PRN IV (Adult): Status Epilepticus- 5-10mg, may repeat 10-15min to total of 30mg IV Push: Undiluted, 5mg/mL concentration, rate of 5mg/min Acute pain, chronic pain Confusion, sedation, constipation, resp. depression BP, pulse, resp. rate, pain assessment Hold if paralytic ileus, resp. rate <10 min BP, pulse, resp. rate, bowel function, pain assessment 1hr after admin Expected: Decrease in severity of pain Anxiety, decrease seizures Dizziness, drowsiness, lethargy, apnea, cardiac arrest Assess mental status (orientation, mood, behavior) Hold if severe hypotension Anxiety, decrease seizures, impaired physical mobility Dizziness, drowsiness, lethargy, resp. depression BP, pulse, resp. rate, mental status Hold if myasthenia gravis, comatose Assess mental status (orientation, mood, behavior) Expected: Decrease in subjective feelings of anxiety, post-op amnesia, improved sleep patterns Assess IV site frequently, BP, pulse, resp. rate Expected: Decrease anxiety level, Post-op amnesia, control of seizures, decrease muscle spasms Antidote: Naloxone (Narcan) ciprofloxacin, Cipro T: antiinfectives PO, IV Skin infections-PO (Adults): 500-750mg q12h for 7-14 days IV (Adults): 400 mg q812h for 7-14 days; dilute with 0.9% NaCI, administer over 60 min Infection Elevated intracranial pressure, seizure, suicidal thoughts, hepatotoxicity, C-diffassociated diarrhea (CDAD) Nephrotoxicity, phlebitis Assess for infection, obtain specimen Hold if history of myasthenia gravis, concurrent use with tizanidine Monitor bowel function and anaphylactic reaction Expected: resolution of the S/S of bacterial infection vancomycin T: antiinfectives IV, PO IV (Adults): 500mg q6h, 4g/day MAX, dilute w/ 10mL of sterile water, infuse over 60 min PO (Adults): 125mg q6h for 10days Infection Assess for infection Hold if hypersensitivity Monitor IV site frequently, BP, I&O Expected: resolution of the S/S of bacterial infection, endocarditis prophylaxis Assess I&O, rash, neurologic status Expected: resolution of S/S of infection metronidazole, Flagyl T: antiulcer agent, anti infectives IV, PO, Topic al, Vag Infection, diarrhea Seizures, dizziness, headache, aseptic meningitis, abdominal pain, anorexia, nausea Assess for infection, obtain specimen Hold if hypersensitivity cefazolin T: antiinfectives P: 1st gen cephalosporins IV, IM PO (Adults): Anaerobic infections -7.5mg/kg q6h, 4g/day MAX IV (Adults): Anaerobic infections- initial dose 15mg/kg, then 7.5mg/kg q6-8h; undiluted over 3060min IM IV (Adults): Modsevere infections500mg-2g q6-8h, 12 g/day MAX, rate of 3060min IV Push: Dilute w/ sterile water, rate at 35min Infection, diarrhea Seizures, CDAD, pain and phlebitis at IV site, rash Assess for infection, obtain specimen Hold if hypersensitivity and allergy to penicillin/ cephalosporins piperacillin/ tazobactam T: anti-infective P: extended spectrum penicillin IV IV (Adults): 3.3375 g q6h, dilute with sterile water concentration of 1g/ 5mL, infuse over 30 min Infection Seizures, CDAD, diarrhea, rashes, pain, phlebitis at IV site, DRESS levofloxacin, Levaquin T: anti-infective P: fluroquinolones PO, IV PO (Adults): 750 mg o.d. for 7-14 days, IV (Adults): 750 mg o.d. for 7-14 days, dilute with 0.9% NaCI for concentration of 5mg/mL, infuse over 90 min Infection Elevated intracranial pressure, seizures, nausea, hepatoxicity, CDAD, suicidal thoughts Assess for infection, obtain specimen Hold if allergy to penicillin, betalactams, cephalosporins, tazobactam Assess for infection, obtain specimen Hold if concurrent use with Class IA/ III antiarrhythmics Potassium Chloride T: mineral/ electrolyte replacement/ supplement PO PO (Adults): 40-80 mEq/day Imbalanced nutrition Abdominal pain, diarrhea, flatulence, nausea, vomiting, arrhythmias Assess for S/S of hypokalemia (weakness, fatigue, arrhythmias) and hyperkalemia Hold if pt. is hyperkalemic, severe renal impairment levothyroxine, Synthroid T: hormones P: thyroid preparations PO, IV, IM PO (Adults): Hypothyroidism-75-125 mcg/day, 1.5 mcg/kg/day IM IV (Adult): Hypothyroidism- 50100mcg/day as single dose Hypothyroidism Only seen in excessive doses: headache, irritability, abdominal cramps, sweating Assess apical pulse, BP Hold if pt. has hyperthyroidism, recent MI Monitor for S/S of CDAD, rash, monitor IV site, changing q4872hr Expected: resolution of S/S of infection, decrease incidence of infection when used for prophylaxis Monitor for CDAD, rash, DRESS (fever, rash, facial swelling) Expected: resolution of S/S of infection Monitor for CDAD, rash, suicidal tendencies, depression, changes in behavior Expected: resolution of S/S of bacteria infection, prevention/ treatment of plague, avoidance of s/s of inhalational anthrax Assess for S/S of hypokalemia Expected: prevention and correction of serum potassium depletion, cessation of arrythmias caused by digoxin toxicity Monitor apical pulse, BP, tachyarrhythmias, chest pain Expected: resolution of symptoms of hypothyroidism and normalization of hormone levels Prednisone T: antiinflammatories (steroidal) (intermediate acting), immune modifiers PO PO (Adults): 5-60 mg/day as a single dose, with meals Infection, autoimmune disorders, inflammation, allergic reaction More common in high dose/ long-term therapy: depression, euphoria, hypertension, acne, nausea, muscle wasting, osteoporosis, cushingoid appearance, decrease wound healing Assess for S/S of adrenal insufficiency (hypotension, weight loss, weakness, confusion) Hold if active untreated infections methylprednisol one, Medrol T: antiinflammatories (steroidal) immunosuppre ssant P: corticosteroids PO, IM, IV PO (Adults): 2-60 mg/day as a single dose, with meals IM IV (Adults): Methylprednisolone sodium succinate-40250 mg q4-6h, diluted MAX concentration 2.5-20mg/mL IM (Adults): Methylprednisolone acetate-40-120 mg daily, weekly, or every 2wk, undiluted, shake suspension well IV Push: Reconstitute with MAX concentration 125 mg/mL, rate at 3-15min Infection, autoimmune disorders, inflammation, allergic reaction More common in high dose/ long-term therapy: depression, euphoria, hypertension, acne, nausea, muscle wasting, osteoporosis, cushingoid appearance, decrease wound healing, peptic ulceration, thromboemboli sm Assess for S/S of adrenal insufficiency Hold if active untreated infections, epidural use Monitor for s/s of adrenal insufficiency, I&O Expected: decrease in presenting symptoms, suppression of the inflammatory/ immune response for autoimmune disorders, allergic reactions, and neoplasms, management of symptoms in adrenal insufficiency Monitor for s/s of adrenal insufficiency, I&O Expected: decrease in presenting symptoms, suppression of the inflammatory/ immune response for autoimmune disorders, allergic reactions, and neoplasms, management of symptoms in adrenal insufficiency Ti m e s Med Class Route & Freq Dosage Why is this pt. taking? Side Effects *Include the recommended dosage range for this age group Medical DX NSG DX Assessment Lab Diluted Un-Diluted Diluted amt. Minutes for injection Tablets: 25 mg, 50 mg, 100 mg HTN, angina pectoris, acute MI Dizziness, orthostatic hypotension, Bradycardia, tachycardia, cardiac arrest, PE, dyspnea Before Giving *Hold if: Atenolol T: antihypertensive P: Beta Blockers PO Check apical pulse, hold if less than 60 bpm and/or systolic BP is less than 100 mmhg PO given with meal, check apical pulse (<60= hold), check BP (systolic <100 mmhg=hold) Give 1 hour before meals, check BP and heart rate (hold if sBP <100 mmhg and apical pulse <60 bpm) Check BP (hold if sBP <100 mmhg) Metoprolol T: Antihypertensive P: Beta Blocker PO, injection Tablets: 25 mg, 50 mg, 100 mg Injection: 1mg/mL in 5 mL ampule HTN, early intervention in MI, angina pectoris, stable symptomatic heart failure Fatigue, bradycardia, HF, stroke, nausea, bronchospasm, rash Captopril T: Antihypertensive P: ACE inhibitor PO Tablets: 12.5 mg, 25mg, 50 mg, 100 mg HTN, diabetic neuropathy, HF, left ventricular dysfunction after acute MI Dizziness, leukopenia, hyperkalemia, dyspnea, angioedema, cough Lisinopril T: Antihypertensive P: ACE inhibitor PO Oral solution: 1 mg/mL Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg HTN, adjunctive treatment for HF, stable pt within 24 hr after acute MI Fatigue, dizziness, diarrhea, hyperkalemia, dyspnea, angioedema, hypotension Diltiazem T: Antihypertensive P: Calcium-channel blocker PO, injection Capsules: 60, 90,120, 180, 240, 300, 360, and 420 mg Injection: 5mg/mL Tablets: 30, 60, 90, 120 mg Headaches, arrythmias, AV block, bradycardia, HF, hypotension, nausea, acute hepatic injury Check BP (<90 mmhg systolic= hold) and HR (<60 bpm=hold) Amiodarone T: Antiarrhythmics P: Benzofuran derivatives IV, PO IV: 50 mg/mL, 150mg/ 100mL, 450 mg/ 9 mL Tablets: 100 mg, 200 mg, 400 mg Manage Prinzmetal or variant angina, HTN, AFib, improvement of exercise tolerance in pt w chronic stable angina Prevention of recurrent ventricular arrythmias (aFib, unstable ventricular tachycardia) Fatigue, ataxia, hypotension, asystole, aFib, bradycardia, arrythmias, HF, heart block, sinus arrest, coagulation abnormalities, hepatic failure, ARDS, pulmonary edema Check BP (<90 mmhg systolic= hold) and HR (<60 bpm=hold) and correct electrolyte imbalances before beginning Digoxin T: Antiarrhythmics, Inotropes P: Cardiac glycosides PO, injection Oral solution: 0.05 mg/mL (peds) Injection: 0.1 mg/mL (peds), 0.25 mg/ mL HF (rapid and gradual digitalization), chronic aFib Fatigue, agitation, muscle weakness, arrythmias, heart block, light flashes, nausea Check HR (hold if <60 bpm at apical) After Giving Assess SE & Expected Outcomes (what should the med do) Continually reassess BP and heart rate EO: lower BP Continually reassess BP and heart rate EO: lower BP Monitor BP and heart rate frequently EO: lower BP Monitor BP and serum potassium levels frequently (can increase BUN, creatinine, potassium levels) EO: lower BP Monitor BP and heart rate EO: lower BP Monitor BP and HR, obtain a baseline of pulmonary, liver, and thyroid function tests results, watch for pulmonary toxicity, monitor potassium and magnesium levels EO: prevention of recurrent lifethreatening antiarrhythmics Monitor pt for toxicity, digoxin level, and potassium level. If HR falls below 60 bpm then withhold medication Tablets: 0.0626 mg, 0.125 mg, 0.25 mg Injection: 10 mg/mL Oral solution: 10 mg/mL, 40 mg/5mL Tablets: 20 mg, 40 mg, 80 mg, 500 mg EO: controls rate and rhythm of heart Furosemide T: Antihypertensive P: Loop diuretic PO, injection Hydrochlorothiazid e (HCTZ) T: Diuretics P: Thiazide diuretics PO Capsules: 12.5 mg Tablets: 12.5 mg, 25 mg, 50 mg Edema, HTN Spironolactone T: Diuretics P: K+ Sparing diuretics PO Tablets: 25 mg, 50 mg, 100 mg Oral suspension: 25 mg/ 5 mL Simvastatin T: Antilipemic P: HMG-CoA reductase inhibitors PO Tablets: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg Edema due to HF, hepatic cirrhosis, or nephrotic syndrome, HTN, diuretic induced hypokalemia, to detect and manage primary hyperaldosteroni sm To reduce the risk of death from CV disease and CV events in pt at high risk for coronary events, reduce total and LDL cholesterol, heterozygous familial hypercholesterol emia in boys and girls PE, DVT, MI, rheumatic heart disease with heart valve damage, prosthetic valves, and chronic aFib Lipid lowering Acute pulmonary edema, edema, HTN Vertigo, headache, agranulocytosis, aplastic anemia, leukopenia, thrombocytopenia, hypokalemia, hypocalcemia, hypomagnesemia, gout Dizziness, pancreatitis, renal failure, aplastic anemia, leukopenia, thrombocytopenia, hypokalemia, hypercalcemia, respiratory distress, erythema, gout Gastric bleeding, renal failure, vomiting, agranulocytosis, hyperkalemia, hyponatremia Check BP (<90 mmhg systolic= hold) and HR (<60 bpm=hold) Monitor pt weight, BP, HR, fluid I&O, electrolyte, BUN, and CO2 levels frequently EO: lower BP Check BP (<90 mmhg systolic= hold), correct electrolyte balances Monitor fluid I&O, weight, BP, electrolyte levels, and creatinine and BUN levels EO: Lower amount of fluid within body Avoid giving foods high in K+, check body weight and BP along with electrolytes (fix imbalances prior) Monitor fluid I&N, weight, renal function, electrolyte levels, and BP closely EO: lower amount of fluid within body Headache, vertigo, edema, aFib, sinusitis, abdominal pain, constipation, nausea, UTI, myalgia, bronchitis, eczema Obtain LFT results before adminstering Monitor pt for myopathy, pt should follow strict diet in saturated fat and cholesterol, and discontinue if signs of jaundice EO: reduce risk of CV event in pt with high total cholesterol Vasculitis, abdominal pain, flatulence, nausea, hemorrhage, hepatitis, pruritus, chills Check INR (how long it takes blood to clot) before administering Frequently check INR and inspect gums for bleeding, bruises on arms and legs, nosebleeds, hematemesis, tarry stool, and monitor for purple-toes syndrome EO: treatment of embolisms and thrombi Monitor platelet count, inspect pt for bleeding gums, nosebleeds, hematemesis, tarry stool, and continue to monitor their vital signs EO: blood thinner to treat/prevent DVT and PE Monitor platelet count, inspect pt for bleeding gums, nosebleeds, hematemesis, tarry stool, and continue Warfarin T: anticoagulants P: coumarin derivatives PO Tablets: 1, 2, 2.5, 3, 4, 5, 6, 7.5, and 10 mg Heparin T: anticoagulant P: anticoagulant IV, SubQ SubQ: 5000 units/ q8-12 hrs IV: 5000 units via IV bolus, then 20,00040,000 units/day via IV infusion with pump Thromboprophyl axis, DVT, or PE Fever, hemorrhage, prolonged clotting time, thrombocytopenia, white clot syndrome, hyperkalemia, osteoporosis Check vital signs and INR Enoxaparin T: anticoagulants P: Low-molecular weight heparins IV, SubQ SubQ: 40mg/day, 1 mg/kg IV: 30 mg IV bolus Treat/prevent PE and DVT, treat acute STsegment elevation MI Confusion, fever, pain, edema, nausea, thrombocytopenia, hemorrhage, dyspnea, angioedema Check INR and vital signs, draw blood to establish baseline coagulation parameters Albuterol T: bronchodilator P: adrenergic PO, inhalation Inhalation aerosol: 100 mcg/ actuation Inhalation powder: 108 mcg/ actuation Syrup: 2 mg/5 mL Tablets: 2 mg, 4 mg Nasal spray: 27.5 mg Oral inhalation aerosol: 44 mcg, 110 mcg, 220 mcg Oral inhalation powder: 50 mcg, 100 mcg, 113 mcg, 200 mcg, 232 mcg, 250 mcg Treat/prevent bronchospasm in COPD pt, acute treatment of moderate to severe hyperkalemia Headache, insomnia, dizziness, palpitations, HTN, tachycardia, chest pain, lymphadenopathy, conjunctivitis, otitis media, pharyngitis, nausea, hypokalemia, bronchospasm, cough Auscultate lung sounds, check electrolyte levels for K+ Fluticasone T: Corticosteroid P: Corticosteroid Inhalation, intranasal Preventative in maintenance of chronic asthma, nasal symptoms of seasonal/ perennial allergic and nonallergic rhinitis, nasal polyps Headache, conjunctivitis, epistasis, laryngitis, abdominal pain, vomiting, osteoporosis, bronchospasm, dyspnea, angioedema, influenza Assess for hx of seasonal allergic rhinitis, obtain vital signs Salmeterol T: bronchodilator P: Long-acting selective beta2 agonists Inhalation Inhalation powder: 50 mcg/dose Long-term maintenance of asthma, prevention of exercise-induced bronchospasms, COPD (emphysema or chronic bronchitis) Anxiety, headache, tachycardia, palpitations, pharyngitis, nausea, back pain, asthma, flulike symptoms Assess for hx of asthma or COPD, obtain vital signs, auscultate lung sounds, take 30 mins before exercise for exerciseinduced asthma Advair Diskus T: antiasthmatics P: Corticosteroidslong-acting beta2 adrenergic agonists Inhalation Advair Diskus 100/50, Advair diskus 250/50, Advair diskus 500/50 Headache, palpitations, pharyngitis, appendicitis, diarrhea, constipation, bronchitis, pneumonia Assess for potential of a lifethreatening episode of asthma=hold medication, obtain vital signs Atrovent T: Bronchodilator P: Anticholinergics Inhalation, intranasal Inhaler: 17 mcg/metered dose Nasal spray: 0.03%; 0.06% Dizziness, headache, palpitations, chest pain, HTN, blurred vision, pharyngitis, nauseas, dyspepsia, dry mouth, constipation, back pain, bronchospasm, cough, dyspnea, flulike symptoms Obtain vital signs, assess for hx of COPD and rhinitis Ranitidine T: Antiacids Agent P: Histamine H2 agent PO, injection Injection: 25 mg/mL Syrup: 15 mg/mL Tablet: 75, 150, 300 mg Treatment for asthma pt not on long-term asthma control medication, maintenance therapy for COPD and reduces their exacerbations Treats bronchospasm in COPD pt, rhinorrhea caused by allergic and nonallergic perennial rhinitis, common cold, and seasonal allergic rhinitis, and acute asthma exacerbations Treats GERD, GI ulcers, heartburn Headache, constipation, abdominal pain, vomiting, irritation at site of injection Assess for porphyria, tarry stool, dyspnea, SOB to monitor their vital signs EO: blood thinner to treat/prevent DVT and PE Monitor for effectiveness and auscultate lung sounds EO: Treat/prevent bronchospasm and lowers potassium levels Monitor respiratory function, for glaucoma and cataracts, and observe pt closely for effects EO: Treat nasal symptoms for seasonal allergic/nonallergic rhinitis, nasal polyps, and preventing exacerbation of asthma attack Reassess vital signs and monitor respiratory function. EO: Prevents exercise-induced bronchospasms, maintains asthma exacerbations, and helps treat and relieve bronchospasms in COPD pt Monitor for urticaria, angioedema, rash, bronchospasm, or other signs EO: Treats bronchospasms of COPD and asthma pt by dilating bronchi Reassess vital signs, observe for bronchospasms EO: Dilates bronchi to prevent and treat bronchospasms in COPD and asthma pt along with pt experiencing rhinitis Reassess for any side effects and assess for hematemesis and tarry stool Famotidine T: Antiulcer drug P: H2 receptor antagonists PO, injection Injection: 0.4 mg/mL, 10 mg/mL Tablets: 10, 20, 40 mg Tablets (chewable): 10, 20 mg Pantoprazole T: antiulcer drugs P: PPIs PO, IV Injection: 40 mg/vial Suspension: 40 mg Tablets (delayed): 20, 40 mg Tablets (entericcoated): 20, 40 mg Omeprazole T: Antiulcer drugs P: PPIs PO Capsules (delayed): 10, 20, 40 mg Powder for oral suspension: 2.5 mg/packet, 10 mg/packet Suspension: 2 mg/mL Tablets (delayed): 20 mg Ondansetron T: Antiemetics P: Selective serotonin receptor antagonists PO, IV, IM Injection: 2 mg/mL, 4 mg/mL Oral solution: 4 mg/5 mL Tablets: 4, 8,24 mg Metoclopramide T: GI stimulants PO, IV, IM Injection: 5 mg/mL Short-term treatment for duodenal ulcer and benign gastric ulcer, pathologic hypersecretory conditions, hospitalized pt who cannot take oral drug or have intractable ulcers or hypersecretory conditions, GERD, and used to prevent/treat heartburn Maintenance of healing of erosive esophagitis, short-term treatment of erosive esophagitis associated with GERD, long-term maintenance of healing erosive esophagitis and GERD, treatment of pathologic hypersecretion caused by Zollinger-Ellison syndrome, and dyspepsia Symptomatic GERD without esophageal lesions, erosive esophagitis, pathologic hypersecretory conditions, dudeonal ulcer, H. pylori infection and duodenal ulcer disease, shortterm treatment for active benign gastric ulcer, frequent heartburn (2+ days), dyspepsia Prevents nausea and vomiting from highly/moderatel y emetogenic chemotherapy, postoperative procedures, and from radiation therapy Prevent or reduce nausea EO: Treatment of GI ulcers, GERD, and heartburn along with discomfort Reassess for abdominal pain after and actively look for blood in emesis, stool, or gastric aspirate EO: Treats duodenal and gastric ulcers, GERD, and prevents/treats heartburn relieving their symptoms and lowering their level of pain Headache, dizziness, irritability, agitation, constipation, diarrhea, vomiting Assess pt for abdominal pain prior to administering Anxiety, insomnia, depression, vertigo, chest pain, edema, thrombophlebitis, pharyngitis, abdominal pain, constipation, diarrhea, dyspepsia, nausea, gastroenteritis, UTI, leukopenia, thrombocytopenia, elevated live enzyme levels, hyperlipidemia, hyperglycemia, dyspnea, pruritus Monitor magnesium levels before administering and assess pain level Continue to monitor magnesium levels as it can low it and look for S/S of low magnesium levels (abnormal HR, palpitations, muscle spasms, tremor, seizures, dizziness, lightheadedness) EO: Treats esophagitis and lowers pt level of pain Asthenia, dizziness, headache, abdominal pain, constipation, diarrhea, flatulence, nausea, vomiting, back pain, weakness, cough, URI, rash Give drug 3060 mins before meals, monitor magnesium levels before administering Continue monitoring magnesium levels and look for S/S of low magnesium levels (abnormal HR, palpitations, muscle spasms, tremor, seizures, dizziness, lightheadedness) EO: Treats pt issue and relieves any pain from ulcers or heartburn by targeting the issue Dizziness, fatigue, headache, malaise, sedation, anxiety. Chest pain, arrythmias, constipation, diarrhea, hypoxia, rash, chills Correct electrolyte abnormalities before infusing the drug Monitor pt for S/S of serotonin syndrome and monitor the LFT results EO: Relief for nausea and vomiting Seizures, suicidal ideation, confusion, Auscultate the abdomen Monitor bowel sounds, involuntary P: dopamine antagonists Oral solution: 5 mg/5 mL Tablets: 5, 10 mg Docusate T: Laxatives P: Surfactants PO, PR (rectally) Senna T: Laxative P: Stimulant laxatives PO Lactobacillus Acidophilus T: Antidiarrhea agent P: Antidiarrhea agent PO Capsules: 50, 100, 250 mg Rectal suspension: 100 mg/5 mL, 282 mg/4 mL Tablets: 100 mg Tablets: 1 tab/day Capsule: 60 mg/day Yogurt: 1-2 per day and vomiting from emetogenic cancer chemotherapy, postop procedure, and facilitate smallbowl intubation, to aid in radiologic exam, delayed gastric emptying secondary to diabetic gastro paresis, and GERD Constipation (stool softener) dizziness, insomnia, bradycardia, supraventricular tachycardia, hypotension, transient HTN, bowel disorders, diarrhea, nausea, agranulocytosis, neutropenia, rash, gynecomastia (hold if hypoactive), obtain vital signs, give medication 30 before meals movements of face, tongue, and extremities, and continue to monitor for fever, irregular pulse, cardiac arrythmias, abnormal BP and dizziness EO: Prevents/reduces nausea and vomiting Throat irritation, bitter taste, mild abdominal cramping, diarrhea, laxative dependence with long-term use Assess if pt has adequate fluid intake, exercise and diet Reassess for bowel movements and frequency along with consistency EO: Increases bowel movements to relieve constipation Constipation (stool softener) Stomach pain or cramps, diarrhea, throat irritation Reassess for bowel movements and frequency along with consistency EO: Increases bowel movements to relieve constipation Maintains normal flora in GI tracts, treats diarrhea, lactose intolerant, Crohn’s disease, and an overgrowth of bacteria in the intestines Bloating, flatulence, anaphylaxis (hives, dyspnea, and edema of face, lips, tongue, and throat) Assess for abdominal pain, rectal bleeding, and any allergies prior to giving this medication No assessment needed; this is a probiotic that maintains normal flora within intestines Assess for any side effects from the probiotic EO: Pt maintains normal flora in intestines and relief from diarrhea
